Erweiterte Suche

Dr. Kuno Sommer ist Verwaltungsratspräsident der Targimmune Therapeutics AG, Verwaltungsratspräsident der Sunstar-Holding AG, Verwaltungsratspräsident der Polyphor AG, Verwaltungsratspräsident der Bachem Holding AG, Verwaltungsratspräsident der PDS Pathology Data Systems Co. Ag, ein Präsident des Verwaltungsrats der Kenta Biotech AG und ein Präsident des Verwaltungsrats der Bachem Americas, Inc. Er ist Mitglied des Verwaltungsrats der Ferienclub Privilge AG. Dr. Sommer war zuvor als Chief Executive Officer bei Harlan Laboratories Ltd., als Chief Executive Officer bei Berna Biotech AG, als Chief Executive Officer bei Givaudan SA, als Principal bei F. Hoffmann-La Roche Ltd., als Chief Business Officer bei Crucell NV, als Head-Contract Research bei Harlan Laboratories Ltd., als Chairman bei Pevion Biotech AG und als Mitglied der Geschäftsleitung bei Roche Holding AG tätig. Er erwarb seinen MBA an der Universität Basel und promovierte an der Universität Basel.

Sachiko Kuno is the founder of VLP Therapeutics LLC (founded in 2012), R-Tech Ueno, Ltd.
(founded in 1989), S&R Technology Holdings LLC (founded in 1999), Sucampo Pharmaceuticals LLC (founded in 1996), Sucampo GmbH (founded in 1997), and S&R Foundation (founded in 2000).
Dr. Kuno's current job(s) include being an Independent Outside Director at Monex Group, Inc. since 2023, a Director at The Henry L.
Stimson Center, and a Trustee at Johns Hopkins Medicine, Inc.Dr. Kuno's former job(s) include being a Director at The Maureen & Mike Mansfield Foundation.
Dr. Kuno's education history includes undergraduate and doctorate degrees from Kyoto University.

Dr. Kuno Jung has eight years experience in the life science and over three years experience in the venture capital industry.
Before joining GLSV, he served as Chief Executive Officer at Timaq medical imaging Inc., a globally active clinical imaging contract research organization since the start of the company in 2003.
Prior to joining Timaq, he co-founded Aravis Ventures in 2001, a life science specific Venture Capital Fund, where he served as investment manager specializing in early-stage Biotech investments which were primarily located in Europe.
From 2000 until 2001 he was Project Manager at LUNAMed AG, Zurich, Switzerland, a cancer therapeutic company.
From 1999 until 2003, he advised a series of Biotech companies for strategic alignment and business development.
For his work with Timaq Medical Imaging Inc., the Swiss Federal Office for Professional Education and Technology (OPET) awarded him the CTI start-up prize in 2004 for the successful build-up of a start-up company.
Kuno holds a PhD in Biotechnology and an MS in food sciences, which he both obtained from the Swiss Federal Institute of Technology (ETH) in Zurich in 1999 and in 1996, respectively.